TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Summary

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)

Timeline

Start

2024-10-29

Primary completion

2028-01-01

Completion

2038-08-01

Drugs

Indications